

Naveni® Plex

ILLUMINATING FUNCTION IN SPATIAL PROTEOMICS

Revolutionize your research with Naveni® Plex

As only a minority of patients receiving immune checkpoint inhibition therapy (ICI) respond to treatment, better **functional** biomarkers to predict and understand response to cancer treatment are urgently needed. A recent study¹ showed that our assay detecting PD1/PD-L1 interactions can more accurately predict responders versus non-responders compared to currently employed companion diagnostics; in this case, PD-L1 expression by IHC. Now you can further uncover complex protein interactions in the tumor microenvironment with **Naveni® Plex**, the groundbreaking *is*PLA multiplex solution **designed to simultaneously detect**:

- **PD1/PD-L1 interactions** – illuminating activated immune checkpoint pathways;
- **CD8/MHC-I interactions** – revealing initiation of critical T-cell activation processes;
- **CD3 presence** – tracking a key T-cell marker.

Why choose Naveni® Plex?

Multiplex *is*PLA providing functional proteomics:


Mapping multiple protein interactions simultaneously in the cancer immune interface, going beyond expression to reveal functionality.

Optimized and ready to use: Curated and validated protein targets for improved understanding of the immune landscape in tissue.

Enhanced sensitivity & specificity: Dual antibody recognition with signal amplification ensures precise detection of even the most challenging targets in a multiplex setting.


Image: PD1/PD-L1 (magenta), CD3/CD3 (teal) and CD8/MHC-I (yellow) simultaneously detected by Naveni® Plex in tonsil. Nuclei (DAPI) in grey.

¹Lindberg, A., et al (2024). *In situ* detection of PD1–PD-L1 interactions as a functional predictor for response to immune checkpoint inhibition in NSCLC. *Journal of Thoracic Oncology*.



How it works

Three pairs of primary antibodies conjugated to proprietary oligonucleotide arms (Navenibodies) are simultaneously incubated with your FFPE tissue sample to detect the interaction between PD1 and PD-L1, CD8 and MHC-I, and two epitopes on the CD3 protein. Only if the Navenibodies are in close proximity will they generate a rolling circle amplification reaction, leading to a strong and distinct signal in the respective channel (FITC, Cy3, or Cy5).



PD1/PD-L1 (magenta), CD3/CD3 (teal) and CD8/MHC-I (yellow) simultaneously detected by Naveni[®] Plex in (A) Hodgkin lymphoma, (B) lung cancer and (C) melanoma. Nuclei (DAPI) in grey.

Ordering information

Easy ordering and fast turnaround. Contact your local distributor at www.navinci.se/distributors or visit us at www.navinci.se/products

Product	Code	Read out	Primary antibodies
Naveni Plex	60000	Fluorescence	Included

Kit size: 4ml working solution.
For research use only. Not for use in diagnostic procedures.



For product-specific images on different tissues and more info, visit our web.
Email: contact@navinci.se